H.C. Wainwright does not see direct read from Roche miss to Olema’s OPERA-02

Core Viewpoint - Roche's persevERA trial has failed, but the frontline opportunity for palazestrant is not considered eliminated by H.C. Wainwright [1] Summary by Relevant Categories Trial Outcomes - The persevERA trial results are described as "disappointing" [1] - The failure of the persevERA trial is not seen as a complete readthrough to Olema Oncology's OPERA-02 trial [1] Investment Perspective - H.C. Wainwright maintains a Buy rating on Olema shares, indicating confidence in the company's prospects despite the trial outcome [1] - The analyst suggests that differences in combination agents could favor the OPERA-02 trial, which is evaluating palazestrant plus ribociclib [1]